{"id":5900,"date":"2019-09-04T17:13:25","date_gmt":"2019-09-04T11:43:25","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5900"},"modified":"2025-05-08T11:45:17","modified_gmt":"2025-05-08T06:15:17","slug":"driving-factors-boosting-the-hepatocellular-carcinoma-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market","title":{"rendered":"Driving factors boosting the Hepatocellular Carcinoma Market"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f2f6642ea99\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f2f6642ea99\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market\/#Hepatocellular_Carcinoma_Market_Trends\" >Hepatocellular Carcinoma Market Trends<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market\/#Durvalumab_plus_Tremelimumab\" >Durvalumab plus Tremelimumab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market\/#BGB-A317\" >BGB-A317<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market\/#ET140202\" >ET140202<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market\/#Other_companies_driving_Hepatocellular_Carcinoma_therapy_market\" >Other companies driving Hepatocellular Carcinoma therapy market<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The present Hepatocellular Carcinoma market size is mainly dominated by the protein Kinase inhibitor i.e., Nexavar (Sorafenib) developed by Bayer is considered the first line of treatment. Followed by the second line of treatments and off label Chemotherapies. <\/p>\n\n\n\n<p>Opdivo, leading drug of\nBristol-Myers Squibb approved only in the US and Stivarga developed by Bayer are\nthe two FDA-approved Hepatocellular Carcinoma treatment drugs that have so far\ncreated a positive effect on HCC Market. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hepatocellular_Carcinoma_Market_Trends\"><\/span><strong>Hepatocellular Carcinoma Market Trends<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The dynamics of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-hepatocellular-carcinoma-pipeline-insight\">Hepatocellular Carcinoma market<\/a><\/strong> is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028, as estimated by DelveInsight. <\/p>\n\n\n\n<p>The Hepatocellular Carcinoma emerging\ntherapies that are going to impact the HCC market are Durvalumab plus\nTremelimumab (AstraZeneca; as First-line for Advanced Hepatocellular\nCarcinoma); SHR-1210 (Jiangsu HengRui Medicine; first-line therapy in Advanced Hepatocellular\nCarcinoma) and BGB-A317 (BeiGene; First-Line Treatment for Unresectable\nHepatocellular Carcinoma); ET140202 (Eureka Therapeutics) and many more.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Durvalumab_plus_Tremelimumab\"><\/span><strong>Durvalumab plus Tremelimumab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p>AstraZeneca intends to file for Durvalumab plus Tremelimumab combination after 2020 in the G8 countries. Developing the combination of Durvalumab plus Tremelimumab, it will be treated as first-line therapy in <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-hepatocellular-carcinoma-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\">Advanced Hepatocellular Carcinoma.<\/a> Recently, the company has announced positive results of the ongoing Phase II trial of in patients with advanced hepatocellular carcinoma. <\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BGB-A317\"><\/span><strong>BGB-A317<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p>Another Pharma giant, Beigene is developing\nBGB-A317 in Phase III as a First-Line Unresectable Hepatocellular Carcinoma Treatment.\nBGB-A317 works by activating and restoring T-cells\u2019 ability to kill cancer\ncells. Activated T-cells are integral to the treatment of cancer as they help\nto kill malignant cells. As stated by the company, BGB-A317 is different from\nthe existing and approved anti-PD-1 antibodies because of its high affinity and\nsuperior target specificity.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ET140202\"><\/span><strong>ET140202<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p>ET140202 is another drug under clinical\ntrials by Eureka Therapeutics. The company initiated the clinical trials of the\ndrug for treating advanced hepatocellular carcinoma, the predominant type of\nliver cancer.<\/p>\n\n\n\n<p>Apart from these, few other companies\nare conducting studies in order to test the efficacy of combination therapies\nfor the advanced hepatocellular carcinoma treatment. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Other_companies_driving_Hepatocellular_Carcinoma_therapy_market\"><\/span><strong>Other companies driving Hepatocellular Carcinoma therapy market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>One such example is LSK BioPharma\nentered into a global clinical collaboration with advanced hepatocellular carcinoma\npatient pool, evaluating the safety and efficacy of LSKBioPharma\u2019s rivoceranib.\n<\/p>\n\n\n\n<p>There are other molecules as well in the early stage of development as well, which are expected to create a positive impact on the Hepatocellular carcinoma market revenue once they enter the market. <\/p>\n\n\n\n<p>For Instance, Genoscience Pharma\nis currently running Phase Ib\/IIa Clinical trial for its leading drug\ncandidate, GNS561 in patients suffering from advanced HCC. <\/p>\n\n\n\n<p>Overall, a robust pipeline filled with novel therapies along with the rising incidence of the disease will lead to a significant boost to the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/interstitial-cystitis-market\">Hepatocellular carcinoma market<\/a><\/strong> revenue generated during the forecast period [2019-2028].<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The present Hepatocellular Carcinoma market size is mainly dominated by the protein Kinase inhibitor i.e., Nexavar (Sorafenib) developed by Bayer is considered the first line of treatment. Followed by the second line of treatments and off label Chemotherapies. Opdivo, leading drug of Bristol-Myers Squibb approved only in the US and Stivarga developed by Bayer are [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5901,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[96,17485,17767,5999,5996,5997,17766],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-5900","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-astrazeneca","tag-beigene","tag-eureka-therapeutics","tag-hcc","tag-hepatocellular-carcinoma","tag-hepatocellular-carcinoma-market","tag-hepatocellular-carcinoma-pipeline","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Hepatocellular Carcinoma Market and Market Drivers | DelveInsight<\/title>\n<meta name=\"description\" content=\"A robust Hepatocellular carcinoma pipeline and the HCC rising incidence is leading to a significant boost in the Hepatocellular carcinoma market...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hepatocellular Carcinoma Market and Market Drivers | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"A robust Hepatocellular carcinoma pipeline and the HCC rising incidence is leading to a significant boost in the Hepatocellular carcinoma market...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-09-04T11:43:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:15:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/blog-4sept.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hepatocellular Carcinoma Market and Market Drivers | DelveInsight","description":"A robust Hepatocellular carcinoma pipeline and the HCC rising incidence is leading to a significant boost in the Hepatocellular carcinoma market...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market","og_locale":"en_US","og_type":"article","og_title":"Hepatocellular Carcinoma Market and Market Drivers | DelveInsight","og_description":"A robust Hepatocellular carcinoma pipeline and the HCC rising incidence is leading to a significant boost in the Hepatocellular carcinoma market...","og_url":"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-09-04T11:43:25+00:00","article_modified_time":"2025-05-08T06:15:17+00:00","og_image":[{"width":750,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/blog-4sept.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market","url":"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market","name":"Hepatocellular Carcinoma Market and Market Drivers | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/blog-4sept.jpg","datePublished":"2019-09-04T11:43:25+00:00","dateModified":"2025-05-08T06:15:17+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"A robust Hepatocellular carcinoma pipeline and the HCC rising incidence is leading to a significant boost in the Hepatocellular carcinoma market...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/blog-4sept.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/blog-4sept.jpg","width":750,"height":410,"caption":"Hepatocellular carcinoma Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/blog-4sept-300x164.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">BeiGene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Eureka Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">HCC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hepatocellular Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hepatocellular Carcinoma market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hepatocellular Carcinoma Pipeline<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">BeiGene<\/span>","<span class=\"advgb-post-tax-term\">Eureka Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">HCC<\/span>","<span class=\"advgb-post-tax-term\">Hepatocellular Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Hepatocellular Carcinoma market<\/span>","<span class=\"advgb-post-tax-term\">Hepatocellular Carcinoma Pipeline<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Sep 4, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Sep 4, 2019 5:13 pm","modified":"Updated on May 8, 2025 11:45 am"},"featured_img_caption":"Hepatocellular carcinoma Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5900"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5900\/revisions"}],"predecessor-version":[{"id":31870,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5900\/revisions\/31870"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5901"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5900"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5900"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}